Yunnan Botanee Bio-Technology Group Co.LTD

XSEC:300957 Stock Report

Market Cap: CN¥20.0b

Yunnan Botanee Bio-Technology GroupLTD Valuation

Is 300957 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300957 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300957 (CN¥47.68) is trading below our estimate of fair value (CN¥67)

Significantly Below Fair Value: 300957 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300957?

Key metric: As 300957 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300957. This is calculated by dividing 300957's market cap by their current earnings.
What is 300957's PE Ratio?
PE Ratio33.8x
EarningsCN¥592.37m
Market CapCN¥20.03b

Price to Earnings Ratio vs Peers

How does 300957's PE Ratio compare to its peers?

The above table shows the PE ratio for 300957 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.5x
300146 Byhealth
29.5x34.8%CN¥20.8b
603868 Shanghai Flyco Electrical Appliance
27.9x16.0%CN¥17.9b
603983 Guangdong Marubi Biotechnology
35.4x24.0%CN¥11.1b
003006 Chongqing Baiya Sanitary Products
37.4x26.1%CN¥10.9b
300957 Yunnan Botanee Bio-Technology GroupLTD
33.8x32.4%CN¥20.0b

Price-To-Earnings vs Peers: 300957 is expensive based on its Price-To-Earnings Ratio (33.8x) compared to the peer average (31.9x).

Price to Earnings Ratio vs Industry

How does 300957's PE Ratio compare vs other companies in the CN Personal Products Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300957 33.8xIndustry Avg. 34.0xNo. of Companies4PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300957 is good value based on its Price-To-Earnings Ratio (33.8x) compared to the CN Personal Products industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is 300957's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300957 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.8x
Fair PE Ratio34.7x

Price-To-Earnings vs Fair Ratio: 300957 is good value based on its Price-To-Earnings Ratio (33.8x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300957 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥47.68
CN¥62.40
+30.9%
27.2%CN¥109.00CN¥43.00n/a16
Nov ’25CN¥52.34
CN¥63.34
+21.0%
25.9%CN¥109.00CN¥43.00n/a16
Oct ’25CN¥62.42
CN¥63.51
+1.8%
26.9%CN¥109.00CN¥43.00n/a15
Sep ’25CN¥42.05
CN¥67.17
+59.7%
21.2%CN¥109.00CN¥50.00n/a15
Aug ’25CN¥47.45
CN¥73.99
+55.9%
19.8%CN¥109.00CN¥51.00n/a14
Jul ’25CN¥48.16
CN¥74.64
+55.0%
18.5%CN¥109.00CN¥60.00n/a14
Jun ’25CN¥53.40
CN¥75.99
+42.3%
18.8%CN¥109.00CN¥60.00n/a15
May ’25CN¥57.16
CN¥83.66
+46.4%
24.9%CN¥125.00CN¥60.00n/a15
Apr ’25CN¥62.05
CN¥92.41
+48.9%
21.6%CN¥125.00CN¥60.00n/a16
Mar ’25CN¥65.43
CN¥100.78
+54.0%
24.1%CN¥142.00CN¥60.00n/a15
Feb ’25CN¥56.75
CN¥100.78
+77.6%
24.1%CN¥142.00CN¥60.00n/a15
Jan ’25CN¥68.17
CN¥109.15
+60.1%
22.1%CN¥160.00CN¥71.00n/a15
Dec ’24CN¥70.70
CN¥112.08
+58.5%
19.5%CN¥160.00CN¥81.60n/a15
Nov ’24CN¥77.05
CN¥122.71
+59.3%
18.0%CN¥160.00CN¥87.00CN¥52.3415
Oct ’24CN¥93.31
CN¥134.22
+43.8%
15.3%CN¥181.00CN¥105.00CN¥62.4215
Sep ’24CN¥105.32
CN¥136.22
+29.3%
18.1%CN¥181.00CN¥93.00CN¥42.0515
Aug ’24CN¥103.93
CN¥146.25
+40.7%
20.7%CN¥197.00CN¥93.00CN¥47.4515
Jul ’24CN¥88.88
CN¥148.05
+66.6%
19.2%CN¥197.00CN¥93.00CN¥48.1615
Jun ’24CN¥92.41
CN¥157.39
+70.3%
14.5%CN¥197.00CN¥118.00CN¥53.4015
May ’24CN¥114.03
CN¥160.82
+41.0%
11.6%CN¥197.00CN¥132.00CN¥57.1615
Apr ’24CN¥128.23
CN¥174.90
+36.4%
12.2%CN¥221.00CN¥145.00CN¥62.0515
Mar ’24CN¥137.88
CN¥193.07
+40.0%
12.6%CN¥229.00CN¥158.00CN¥65.4314
Feb ’24CN¥141.50
CN¥199.71
+41.1%
14.4%CN¥264.00CN¥159.00CN¥56.7514
Jan ’24CN¥149.24
CN¥201.99
+35.3%
13.0%CN¥264.00CN¥162.50CN¥68.1714
Dec ’23CN¥132.40
CN¥201.99
+52.6%
13.0%CN¥264.00CN¥162.50CN¥70.7014
Nov ’23CN¥154.50
CN¥214.84
+39.1%
10.8%CN¥264.00CN¥171.00CN¥77.0515

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Sirio Pharma

CN¥6.1b

Operates as a contract manufacturer for dietary supplement industry worldwide.

300791

CN¥26.32

7D

-3.9%

1Y

-4.1%

SYoung Group

CN¥4.8b

Engages in the research and development, production, and sale of cosmetic products in China.

300740

CN¥12.41

7D

-4.2%

1Y

-24.6%

SYoung Group

CN¥4.8b

Engages in the research and development, production, and sale of cosmetic products in China.

300740

CN¥12.57

7D

-3.3%

1Y

-24.9%